All Pfizer published press releases by date and/or category of news
08.22.2022 Vaccines Vaccines Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine 08.19.2022 Financial Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 08.12.2022 Vaccines Vaccines Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants 08.08.2022 Research and Pipeline Research Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 08.08.2022 Financial Investments Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology 08.05.2022 Prescription Medicines Medicines Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis 07.28.2022 Financial Finance PFIZER REPORTS SECOND-QUARTER 2022 RESULTS 06.30.2022 Prescription Medicines Medicines Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™ 06.29.2022 Vaccines COVID-19 Vaccines Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine 06.28.2022 Financial Investments Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus 06.25.2022 Vaccines Vaccines Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron 06.24.2022 Financial Finance Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
The latest news from Pfizer and its strategic partners
04.27.2022 Corporate Partnerships Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer 04.26.2022 Partnerships Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
United States, Canada and Latin America
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.